3,210 Shares in UiPath Inc. (NYSE:PATH) Acquired by Rakuten Securities Inc.

Rakuten Securities Inc. purchased a new stake in UiPath Inc. (NYSE:PATH) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,210 shares of the healthcare company’s stock, valued at approximately $80,000.

Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. raised its position in UiPath by 7.6% during the 3rd quarter. Vanguard Group Inc. now owns 37,750,773 shares of the healthcare company’s stock worth $645,916,000 after purchasing an additional 2,673,718 shares during the last quarter. BlackRock Inc. increased its stake in shares of UiPath by 32.1% in the second quarter. BlackRock Inc. now owns 23,376,854 shares of the healthcare company’s stock valued at $387,354,000 after buying an additional 5,681,577 shares during the period. FMR LLC raised its position in shares of UiPath by 2.9% during the third quarter. FMR LLC now owns 16,238,176 shares of the healthcare company’s stock worth $277,835,000 after acquiring an additional 463,032 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of UiPath by 37.4% in the second quarter. Goldman Sachs Group Inc. now owns 11,662,087 shares of the healthcare company’s stock worth $193,241,000 after acquiring an additional 3,172,300 shares during the period. Finally, Altimeter Capital Management LP boosted its holdings in UiPath by 175.4% in the first quarter. Altimeter Capital Management LP now owns 8,275,000 shares of the healthcare company’s stock valued at $71,579,000 after acquiring an additional 5,270,194 shares during the last quarter. Institutional investors and hedge funds own 62.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on PATH shares. Wells Fargo & Company raised their price target on shares of UiPath from $24.00 to $25.00 and gave the stock an “equal weight” rating in a report on Thursday, March 14th. TD Cowen boosted their target price on shares of UiPath from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, March 14th. Bank of America increased their price target on UiPath from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, March 14th. Truist Financial restated a “buy” rating and set a $32.00 target price on shares of UiPath in a research report on Wednesday, March 20th. Finally, Evercore ISI lifted their target price on UiPath from $24.00 to $27.00 and gave the stock an “in-line” rating in a report on Thursday, March 14th. Nine equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, UiPath has an average rating of “Moderate Buy” and a consensus target price of $27.41.

Insider Activity

In related news, CFO Ashim Gupta sold 16,000 shares of UiPath stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $22.84, for a total value of $365,440.00. Following the sale, the chief financial officer now owns 87,505 shares of the company’s stock, valued at approximately $1,998,614.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 72,000 shares of company stock valued at $1,591,360 in the last three months. Company insiders own 31.03% of the company’s stock.

UiPath Stock Down 1.5 %

Shares of NYSE PATH opened at $19.12 on Thursday. The company has a market capitalization of $10.88 billion, a PE ratio of -112.46 and a beta of 0.96. The stock’s 50 day moving average price is $23.07 and its 200-day moving average price is $21.46. UiPath Inc. has a twelve month low of $12.38 and a twelve month high of $27.87.

UiPath (NYSE:PATH) last released its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The company had revenue of $405.25 million for the quarter, compared to analysts’ expectations of $383.32 million. As a group, research analysts expect that UiPath Inc. will post -0.04 EPS for the current fiscal year.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.